title: CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: usefulness of in vitro apoptosis in leukemic cells.
abstract: A 67-year-old woman was treated for acute myelogenous leukemia with trilineage dysplasia (AML-TLD) by combination chemotherapy with cytarabine, aclarubicin plus macrophage colony-stimulating factor (M-CSF) (referred to as CAM therapy). Complete remission was achieved after two courses of CAM therapy. After coculture of her bone marrow mononuclear cells with M-CSF in vitro, differentiation of leukemic cells into macrophages with apoptotis was observed. This case confirms an earlier report that an effect of M-CSF inducible by differentiation with apoptotic phenomena, against human leukemic cells was shown both in vitro and in vivo when achieving complete remission.
authors.affiliation: Department of Hematology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi 329-0498, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Hatake
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Takatoku
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: M
authors.initials: M
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Kametaka
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: Y
authors.initials: Y
authors.lastname: Terui
authors.forename: H
authors.initials: H
authors.lastname: Tomizuka
authors.forename: K
authors.initials: K
authors.lastname: Muroi
authors.forename: K
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000473:pathology; D018920:Coculture Techniques; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000473:pathology; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D016173:Macrophage Colony-Stimulating Factor